

SC DEPARTMENT OF LABOR, LICENSING, & REGULATION – BOARD OF PHARMACY

*Newsletter to Promote Pharmacy
and Drug Law Compliance.*

Welcome New Board Members Larry Meek and Jarrod B. Tippins

The South Carolina Department of Labor, Licensing, & Regulation – Board of Pharmacy welcomes two new members as of June 30, 2025. Larry Meek, RPh, represents the Fifth Congressional District; this seat was previously held by Heather Harris, PharmD, whose term ran through

June 30, 2025. Jarrod B. Tippins, PharmD, RPh, represents the Seventh Congressional District; this seat was previously held by Archie “Artie” McKnight II, RPh, whose term ran through June 30, 2025.

New Board Chair and Vice Chair Elected

The Board elected new leadership to serve from 2025-2026: Michael Bedenbaugh, MS, MBA, PharmD, was elected chair, and Mary Douglass Smith, PharmD, was elected to serve as vice chair.

*Access the National
Pharmacy Compliance News*

*A Service of the National
Association of Boards of Pharmacy
Foundation® (NABPF®)*



Reminders About Board Notices

Permit holders shall report the following to the Board within 30 working days upon the discovery of the occurrence:

- theft or loss of drugs or devices; or
- conviction of any employee under any state or federal drug law.

Reminders About Board Notices

(cont)

Permit holders shall report the following to the Board within 10 working days upon the discovery of occurrence:

- permanent closing;
- change of ownership, management, location, consultant pharmacist(s), or pharmacist-in-charge (PIC) of a pharmacy;
- change of employment of pharmacists or pharmacy technicians within a pharmacy permitted by the Board; or
- disasters, accidents, destruction, or loss of records required to be maintained by state or federal law.

Pharmacists, pharmacy technicians, and pharmacy interns shall report the following to the Board within 10 working days of occurrence:

- change of mailing address; or
- change of employment.

PICs should notify the Board immediately of any of the following changes:

- change in status of the PIC;
- change of ownership;
- change of address; or
- permanent closing of the pharmacy.

Pharmacy interns shall notify the Board within 10 days of the beginning of each calendar year in which they are employed of the identity of the internship site and the designated pharmacist. Any intern hours submitted without a notice of employment on file have been and will continue to be denied.

Forms for these notifications are available on the Board [website](#).



Reminder on Behalf of DEA and DPH's Bureau of Drug Control

Facilities that store, dispense, and/or possess controlled substances (CS) should notify Drug Enforcement Administration (DEA) and the Bureau of Drug Control, within the South Carolina Department of Public Health (DPH), of an upcoming change of location before moving any CS.

Board Meeting Notes

Below are some of the items discussed at the recent Board meeting:

- The Practice & Technology Committee will be drafting guidance regarding the use and expectations of automated dispensing systems for the Board to consider in the future.
- Compounding regulations continue to be drafted and will be further reviewed at upcoming meetings.
- The Board approved a permit reinstatement process for lapsed permits, which will be implemented over the coming months.
- The Board approved the permitting of contract manufacturers. More information will be available on the Board's website as this new permit is implemented.


FDA Discretion Periods End for Compounding Tirzepatide and Semaglutide

Food and Drug Administration (FDA) has issued timelines for state-licensed pharmacies and outsourcing facilities that compound tirzepatide and semaglutide.

State-Licensed Pharmacies	Tirzepatide	Semaglutide
State-licensed pharmacies or physicians compounding, dispensing, or distributing under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act)	Enforcement discretion for compounding tirzepatide has ended.	Enforcement discretion for compounding semaglutide has ended.

Outsourcing Facilities	Tirzepatide	Semaglutide
Outsourcing facilities compounding, distributing, or dispensing under Section 503B of the FD&C Act	Enforcement discretion for compounding tirzepatide has ended.	Enforcement discretion for compounding semaglutide has ended.

Information about the policies for compounders of tirzepatide and semaglutide injection products can be found on [FDA’s website](#).



Insights That Matter –
Read NABP *Innovations*!

Stay informed on pharmacy regulation trends and NABP updates.

Don't miss the latest *Innovations*®!

The South Carolina Board of Pharmacy News is published by the South Carolina Board of Pharmacy and the National Association of Boards of Pharmacy Foundation® (NABPF®) to promote compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABPF or the Board unless expressly so stated.

Kayce Shealy, PharmD, BCPS, CDCES - State News Editor
Lemrey “Al” Carter, PharmD, MS, RPh - National News Editor & Executive Editor
Megan Pellegrini - Publications and Editorial Manager

Kingstree Bldg, 110 Centerview Dr | Columbia, SC 29210 | www.llr.sc.gov/bop | 803/896-4700